Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 3Gastrointestinal 3Breast 3Thoracic 2Head & Neck 2Genitourinary 2Dermatologic 1

Conditions

Head and Neck Neoplasms 13Squamous Cell Carcinoma of Head and Neck 8Uterine Cervical Neoplasms 7Anus Neoplasms 7Ovarian Neoplasms 6Nasopharyngeal Carcinoma 6Melanoma 6Vaginal Neoplasms 5Stomach Neoplasms 5Penile Neoplasms 5Oropharyngeal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Neoplasm Metastasis 4Esophageal Neoplasms 4Vulvar Neoplasms 3Pancreatic Neoplasms 3Neoplasms 3Colorectal Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Carcinoma, Merkel Cell 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Lung Neoplasms 2Hodgkin Disease 2Endometrial Neoplasms 2Carcinoma, Hepatocellular 2

Interventions

pembrolizumab 19Paclitaxel 6Trastuzumab 5Nivolumab 5palbociclib 4Carboplatin 4Biopsy 4lenvatinib 3Taxes 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Immunoglobulin G 3Fulvestrant 3Cyclophosphamide 3Cetuximab 3trastuzumab deruxtecan 2tisotumab vedotin 2spartalizumab 2sargramostim 2gedatolisib 2fludarabine 2epacadostat 2capivasertib 2X-Rays 2Sunitinib 2Docetaxel 2Disulfides 2Cisplatin 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × fludarabine × Head & Neck × Clear all
NCT04319757 2024-12-05

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Acepodia Biotech, Inc.

Phase 1 Completed
12 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05069935 2023-09-21

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
16 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡